How should tranexamic acid be given intravenously (IV)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 27, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

How to Give Tranexamic Acid IV

Administer tranexamic acid 1 g (100 mg/mL) intravenously at 1 mL/minute (over 10 minutes), with a second 1 g dose if bleeding continues after 30 minutes or restarts within 24 hours. 1

Dosing and Administration

Standard Dosing

  • Initial dose: 1 g IV infused at 1 mL/minute (10-minute infusion) 1
  • Second dose: Additional 1 g IV if bleeding persists after 30 minutes or recurs within 24 hours 1
  • Alternative dosing: 10 mg/kg actual body weight as a single dose, infused no faster than 1 mL/minute 2

Critical Timing Considerations

Give tranexamic acid as early as possible within 3 hours of injury or bleeding onset. 1, 3 The benefit decreases by 10% for every 15-minute delay, with no benefit—and potential harm—after 3 hours. 1 This 3-hour window is absolute and applies across all bleeding contexts.

Infusion Rate Warning

Never exceed 1 mL/minute infusion rate to avoid hypotension. 2 This is a critical safety measure that must be followed regardless of clinical urgency.

Renal Dosing Adjustments

For patients with renal impairment, reduce dosing as follows 2:

  • Serum creatinine 1.36-2.83 mg/dL: 10 mg/kg twice daily
  • Serum creatinine 2.83-5.66 mg/dL: 10 mg/kg once daily
  • Serum creatinine >5.66 mg/dL: 10 mg/kg every 48 hours OR 5 mg/kg every 24 hours

Preparation and Compatibility

  • Inspect solution for particulate matter and discoloration before administration 2
  • May be mixed with electrolyte solutions, carbohydrate solutions, amino acid solutions, and Dextran solutions 2
  • Heparin may be added to tranexamic acid injection 2
  • DO NOT mix with blood products 2
  • DO NOT mix with penicillin-containing solutions 2
  • Diluted mixture may be stored up to 4 hours at room temperature 2

Context-Specific Applications

Postpartum Hemorrhage

The WHO strongly recommends early TXA use (within 3 hours of birth) for clinically diagnosed PPH (>500 mL vaginal birth or >1000 mL cesarean section). 1 Give regardless of bleeding etiology—whether from trauma or uterine atony. This represents a broader indication than previous recommendations that required failure of oxytocin first.

Trauma with Hemorrhagic Shock

For trauma patients with life-threatening hemorrhage and shock, administer 1-2 g (15-30 mg/kg) as early as possible, ideally in the prehospital setting. 4, 3 Current evidence supports either a 1 g dose (followed by hospital-based 1 g infusion over 8 hours) or a 2 g dose as infusion or slow push. 3

Hemophilia Patients (Dental Procedures)

Give 10 mg/kg IV immediately before tooth extraction, then may continue 10 mg/kg 3-4 times daily for 2-8 days post-extraction. 2

Absolute Contraindications

  • Subarachnoid hemorrhage (risk of cerebral edema and infarction) 2
  • Active intravascular clotting 2
  • Known thromboembolic event during pregnancy 1
  • Severe hypersensitivity to tranexamic acid 2

Safety Considerations and Adverse Events

Thromboembolic Risk

The thromboembolic risk is dose-dependent with a marked increase at 4 g (HR 5.33). 4 At standard 1-2 g dosing, the risk appears acceptable when weighed against mortality benefit in hemorrhagic shock, but avoid concomitant use with Factor IX or other prothrombotic agents. 2

Route-Specific Warning

FOR INTRAVENOUS USE ONLY. 2 Inadvertent neuraxial injection can cause seizures. 2 Recent evidence suggests intramuscular administration is being studied as an alternative that may be equally effective with potentially fewer side effects, but IV remains the standard route. 5

Monitoring for Complications

Watch for visual disturbances, seizures (particularly with high doses or inadvertent neuraxial administration), hypotension (if infused too rapidly), and thromboembolic events (DVT, PE). 2, 6 Discontinue immediately if visual symptoms occur. 2

Common Pitfalls to Avoid

  • Do not give beyond 3 hours post-bleeding onset—this is potentially harmful 1
  • Do not infuse faster than 1 mL/minute—causes hypotension 2
  • Do not use extended high-dose regimens (24-hour infusions)—these increase adverse events without improving outcomes 6
  • Do not withhold in PPH waiting for uterotonic failure—give early as part of standard treatment 1
  • Do not use in patients without hemorrhagic shock in trauma—no mortality benefit and potential harm 3

References

Related Questions

What are the indications for tranexamic acid injection?
Is it safe to prescribe tranexamic acid to a patient who smokes half a pack of cigarettes daily?
What concentration should be used to administer a 2‑gram slow intravenous push of tranexamic acid?
After initiating oral tranexamic acid (1 g every 8 hours, up to 3 g per day) for bleeding, at what day does improvement plateau and no further benefit occur?
What is the recommended concentration of tranexamic acid (TXA) for rapid intravenous or intra‑osseous administration in a combat environment?
What is the appropriate atropine dosing and administration for carbamate poisoning?
What is the appropriate atropine dosing regimen for an adult (and pediatric) patient with suspected carbamate poisoning?
At 29 weeks gestation, a pregnant woman reports vaginal spotting; what management steps should be taken?
How should I manage a 29‑week pregnant patient with a grade 2 low‑lying placenta, breech presentation, and vaginal spotting?
What is the appropriate dose of D‑penicillamine for children with Wilson disease?
What is the role of transesophageal echocardiography (TEE) in percutaneous atrial septal defect (ASD) closure?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.